cmcmaster/rheumatology-biologics-dataset-monthly

pbs_code string	drug string	brand string	formulation string	indication string	treatment_phase string	streamlined_code float64	online_application bool	authority_method string	hospital_type string	maximum_prescribable_pack float64	maximum_quantity_units float64	schedule_code string	schedule_year int64	schedule_month string
9662M	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9662M	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9662M	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9662M	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9662M	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9663N	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Public	1	2	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9671B	Tocilizumab	Actemra	Concentrate for injection 80 mg in 4 mL	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9672C	Tocilizumab	Actemra	Concentrate for injection 200 mg in 10 mL	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 1 (new patient)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	First continuing treatment	null	false	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9673D	Tocilizumab	Actemra	Concentrate for injection 400 mg in 20 mL	rheumatoid arthritis	First continuing treatment - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	1	2026-01	2,026	JANUARY
9679K	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9679K	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled syringe	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 1 (new patient)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hyrimoz	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Hadlima	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Amgevita	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY
9680L	Adalimumab	Abrilada	Injection 40 mg in 0.8 mL pre-filled pen	juvenile idiopathic arthritis	Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply	null	true	AUTHORITY_REQUIRED	Private	1	2	2026-01	2,026	JANUARY

9662M

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9662M

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9662M

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9662M

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9662M

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9663N

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Public

1

2

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9671B

Tocilizumab

Actemra

Concentrate for injection 80 mg in 4 mL

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9672C

Tocilizumab

Actemra

Concentrate for injection 200 mg in 10 mL

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 1 (new patient)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

First continuing treatment

null

false

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9673D

Tocilizumab

Actemra

Concentrate for injection 400 mg in 20 mL

rheumatoid arthritis

First continuing treatment - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9679K

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled syringe

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 1 (new patient)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months)

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hyrimoz

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Hadlima

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Amgevita

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY

9680L

Adalimumab

Abrilada

Injection 40 mg in 0.8 mL pre-filled pen

juvenile idiopathic arthritis

Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply

null

true

AUTHORITY_REQUIRED

Private

1

2

0

2026-01

2,026

JANUARY